EHA Plenary: Drug & Molecular Insights
- Early research suggests a novel trispecific antibody, JNJ-79635322, may offer a new treatment avenue for patients with relapsed or refractory multiple myeloma.
- Also at the meeting, investigators shared insights into the genesis of chronic lymphocytic leukemia (CLL) and refined acute myeloid leukemia (AML) classification using machine learning.
- According to session chair Martin Dreyling, MD, of LMU Hospital Munich, molecular and genetic research is fueling clinical therapy improvements for hematologic disorders.
Discover promising advancements in hematology! This insightful report from News Directory 3 unveils the latest findings presented at the European Hematology Association (EHA) Congress. Explore how a novel trispecific antibody demonstrates potential in treating multiple myeloma, offering new hope for patients. Further, the congress highlights advancements in lymphoma and leukemia therapies. Uncover critical breakthroughs, including the submission of machine learning to refine acute myeloid leukemia (AML) classification, enabling more personalized treatment approaches. See how essential thrombocythemia and myelodysplastic syndromes are being addressed. Discover what’s next in this evolving field.
Novel Trispecific Antibody Shows promise in Myeloma Treatment
Updated june 16, 2025
Early research suggests a novel trispecific antibody, JNJ-79635322, may offer a new treatment avenue for patients with relapsed or refractory multiple myeloma. Findings were presented by Rakesh Popat, MBBS, phd, of University Collage London, at the European Hematology Association (EHA) Congress in Milan.
Also at the meeting, investigators shared insights into the genesis of chronic lymphocytic leukemia (CLL) and refined acute myeloid leukemia (AML) classification using machine learning.
According to session chair Martin Dreyling, MD, of LMU Hospital Munich, molecular and genetic research is fueling clinical therapy improvements for hematologic disorders.
other studies presented at the EHA Congress included:
Diffuse Large B-Cell Lymphoma (DLBCL): The phase 3 POLARGO trial, presented by Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Centre, found that polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) improved outcomes in relapsed or refractory DLBCL.
Essential Thrombocythemia: Ropeginterferon alfa-2b demonstrated better safety and efficacy than anagrelide as a second-line treatment for essential thrombocythemia, according to results from the SURPASS-ET trial. Harry Gill, MD, presented the findings.
Myelodysplastic Syndromes: A phase 3 trial led by David Curtis showed that post-transplant cyclophosphamide, when combined with cyclosporin, significantly improved survival without graft-versus-host disease (GVHD) or relapse in patients undergoing stem cell transplantation for myelodysplastic syndromes. At 3 years post-transplant, 49% of patients in the cyclophosphamide arm survived without GVHD or relapse, compared to 14% in the standard-of-care arm (cyclosporin plus methotrexate). Curtis noted no increase in cancer recurrence with the new regimen.
Ian Márquez-López, of Hospital Clinic Barcelona, presented research into CLL, revealing that CLL clones appear to originate from distinct cells and expand decades before diagnosis.
Amin Turki, MD, PhD, of University Hospital Bochum in Germany, presented findings on AML classification using machine learning, identifying 17 distinct biological clusters with varying overall survival rates.
CLL clones seem to arise from distinct cells of origin and start to expand decades before diagnosis of the disease.
What’s next
Turki said that further research could explore the associations among genetic signatures, treatment patterns, and outcomes, possibly personalizing outcome prediction.